CN Patent

CN112055593A — 包含(2s)-n-{(1s)-1-氰基-2-[4-(3-甲基-2-氧代-2,3-二氢-1,3-苯并噁唑-5-基)苯基]乙基}-1,4-氧杂氮杂环庚烷-2-甲酰胺的药物组合物

Assigned to AstraZeneca AB · Expires 2020-12-08 · 5y expired

What this patent protects

本公开涉及适合用于口服给药的药物组合物，特别涉及药物组合物，包括药物片剂组合物，其包含(2S)‑N‑{(1S)‑1‑氰基‑2‑[4‑(3‑甲基‑2‑氧代‑2,3‑二氢‑1,3‑苯并噁唑‑5‑基)苯基]乙基}‑1,4‑氧杂氮杂环庚烷‑2‑甲酰胺(化合物A)或其药学上可接受的盐。

USPTO Abstract

本公开涉及适合用于口服给药的药物组合物，特别涉及药物组合物，包括药物片剂组合物，其包含(2S)‑N‑{(1S)‑1‑氰基‑2‑[4‑(3‑甲基‑2‑氧代‑2,3‑二氢‑1,3‑苯并噁唑‑5‑基)苯基]乙基}‑1,4‑氧杂氮杂环庚烷‑2‑甲酰胺(化合物A)或其药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN112055593A
Jurisdiction
CN
Classification
—
Expires
2020-12-08
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.